Anterior Gradient Protein 2 Promotes Mucosal Repair in Pediatric Ulcerative Colitis

Xiaolin Ye1, Jie Wu1, Jing Li2

  • 1Department of Gastroenterology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

Insights

Anterior gradient protein 2 (AGR2) is elevated in children with ulcerative colitis (UC) and promotes intestinal mucosal repair by activating YAP, suggesting its potential as a biomarker for UC.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Pediatric Medicine

Background:

  • Mucosal healing is a primary treatment objective in ulcerative colitis (UC).
  • Anterior gradient protein 2 (AGR2) is implicated in intestinal homeostasis, but its role in mucosal repair is unclear.
  • Investigating AGR2's function in pediatric UC mucosal injury is crucial.

Purpose of the Study:

  • To examine AGR2 expression in pediatric UC patients.
  • To elucidate AGR2's role in repairing intestinal mucosal injury.
  • To explore the molecular mechanisms underlying AGR2's function in UC.

Main Methods:

  • Compared AGR2 expression in intestinal tissues of UC patients and healthy controls using immunohistochemistry.
  • Evaluated UC disease activity and endoscopic severity.
  • Utilized in vitro models to assess AGR2's effect on TNF-α-induced intestinal epithelial barrier injury and YAP activation.

Main Results:

  • UC patients exhibited significantly higher intestinal AGR2 expression than controls.
  • AGR2 expression positively correlated with Ki67 (cell proliferation) and negatively with endoscopic mucosal injury.
  • In vitro, AGR2 overexpression enhanced cell proliferation, migration, and protected against TNF-α-induced barrier damage via YAP activation.

Conclusions:

  • AGR2 may serve as a valuable biomarker for assessing UC condition and mucosal healing status.
  • AGR2 promotes intestinal mucosal barrier repair by activating YAP.
  • Findings highlight AGR2's therapeutic potential in pediatric UC.

Related Concept Videos

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
734
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
749
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
881
Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.8K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.2K
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
1.0K